{"name":"Casa Sollievo della Sofferenza IRCCS","slug":"casa-sollievo-della-sofferenza-irccs","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Peg Interferon alpha2b + Ribavirin","genericName":"Peg Interferon alpha2b + Ribavirin","slug":"peg-interferon-alpha2b-ribavirin","indication":"Chronic hepatitis C virus infection","status":"phase_3"},{"name":"Peginterferon alpha-2a + Ribavirin","genericName":"Peginterferon alpha-2a + Ribavirin","slug":"peginterferon-alpha-2a-ribavirin","indication":"Chronic hepatitis C","status":"phase_3"}]}],"pipeline":[{"name":"Peg Interferon alpha2b + Ribavirin","genericName":"Peg Interferon alpha2b + Ribavirin","slug":"peg-interferon-alpha2b-ribavirin","phase":"phase_3","mechanism":"Pegylated interferon alpha-2b activates innate immunity to suppress viral replication, while ribavirin inhibits viral RNA synthesis through multiple mechanisms.","indications":["Chronic hepatitis C virus infection"],"catalyst":""},{"name":"Peginterferon alpha-2a + Ribavirin","genericName":"Peginterferon alpha-2a + Ribavirin","slug":"peginterferon-alpha-2a-ribavirin","phase":"phase_3","mechanism":"Peginterferon alpha-2a is a recombinant form of interferon-alpha-2a, which is a protein that helps to stimulate the body's immune response to viral infections, while Ribavirin is an antiviral medication that inhibits viral replication.","indications":["Chronic hepatitis C","Chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1tWWg4MzhjeDdJNVFNNjhLVlRrdS1tNVlXTFhhWjBOVGxWSXVySGtjUDBSZTIzY2ZQWVdHTVYxSVdaS0pvSkdnYVE1QlFfdTZDRGhyMDB3d2dEeENwMHVv?oc=5","date":"2025-09-03","type":"earnings","source":"Nature","summary":"Closing the gap in HCV care: strategic collaboration between industry, academic, community, and nonprofit researchers - Nature","headline":"Closing the gap in HCV care: strategic collaboration between industry, academic, community, and nonprofit researchers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE4wWUg1ZUpQR0UzTjhaanptY0d2RmM0SkRsNkU0TmRva0t1LUYtdW42XzJycDFCR0NJUnRBd3RaTzhVRjVTdGdoZTdfNDIxWFVIQVpTSVQ3OHhCaDNwRU1GSE5ObjZzZkdYdS1iRzRselo?oc=5","date":"2024-12-23","type":"pipeline","source":"Wiley Online Library","summary":"DNA Mimic Foldamer Recognition of a Chromosomal Protein - Wiley Online Library","headline":"DNA Mimic Foldamer Recognition of a Chromosomal Protein","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNUjBzUXc4Q3B4Q1A2TVpUTE03YkFYV3JKdW1IZ2lVTEJfelEzcG5TLXZ4WTBrUWhiUWF2QUpxakpYd3ZTMi1wOGN4alhvanBralRpQ3gwdUUwc2RDRGtCQ21iX0xLQUQwRjl6QkJGS01ybWp6TERNRk1uQ3VuLTZKbi16UklwMTR0bFZSTnBB?oc=5","date":"2024-02-09","type":"trial","source":"Frontiers","summary":"Linking Individual Patient Data to Estimate Incidence and Prevalence of Parkinson's Disease by Comparing Reports of Neurological Services and Pharmacy Prescription Refills at a Nationwide Level - Fron","headline":"Linking Individual Patient Data to Estimate Incidence and Prevalence of Parkinson's Disease by Comparing Reports of Neur","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBRZnZRbGhWelRnX2hGTG5lTi1XRF9lUXlSVDNORmM5d1RWd1dqenhlcExITmJ2VE83c3A3Q2pwamI0eTgyX055RWFPMElsSlFOTzFLOEdPQWN4bXR2Mmtz?oc=5","date":"2023-04-05","type":"pipeline","source":"Nature","summary":"Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRAS - Nature","headline":"Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRAS","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}